Novo Nordisk Plans to Launch CagriSema Weight-Loss Drug in 2027

NVO-0.10%
Novo Nordisk plans to launch CagriSema, a weight-loss medication, next year. The company has determined optimal pricing for the oral version of Wegovy and intends to expand its business portfolio through strategic acquisitions.
Disclaimer: The information on this page may come from third-party sources and is for reference only. It does not represent the views or opinions of Gate and does not constitute any financial, investment, or legal advice. Virtual asset trading involves high risk. Please do not rely solely on the information on this page when making decisions. For details, see the Disclaimer.
Comment
0/400
No comments